Breakthrough: An image from a video provided by Biogen where vials of the medication aducanumab are handled by machines during manufacturing. — AP
NEW YORK: The approval of Biogen Inc’s new Alzheimer’s disease treatment spurred broad gains in the sector, driving the Nasdaq Biotech Index to surge by the most in seven months.
Shares of Eli Lilly & Co jumped 10% and closed at a record high, while Biogen’s partner in Japan, Eisai Co, surged 56% in US trading, the biggest gain ever for the stock. Small-cap companies working on treatments for the disease also climbed: Cassava Sciences Inc rose 5.4%, while Annovis Bio Inc gained 7.4%.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
